Marrow-Tech Inc. said Wednesday that it has received Food andDrug Administration approval to expand clinical trials ofDermagraft, its living dermal replacement product, from 12 to24 burn centers.
The La Jolla, Calif.-based company is also conducting trials ofDermagraft to treat chronic venous skin ulcers, and it hopes toadd a third trial to treat patients with decubitus ulcers by theend of next January.
The company's stock (NASDAQ:MAROA) picked up $2, closing at$15 on Wednesday.
(c) 1997 American Health Consultants. All rights reserved.